November 14th, 2016 by aveciapharma
MILFORD, MA – Nitto Avecia Inc. (Avecia) today released its progress in expanding the company’s analytical development and oligonucleotide manufacturing capacities. The announcement signals the continuation of Avecia’s robust growth strategy to significantly increase its oligonucleotide drug substance manufacturing capacity in Milford, MA along with the addition of drug product capacity in Irvine, CA and analytical development capabilities in Irvine, CA and Marlboro, MA.
Avecia, a recognized leader in therapeutic nucleic acid manufacturing, is in advanced stages to build a new oligonucleotide drug substance manufacturing facility with additional capacity of more than 1.5mol. Earlier this year, a new 300mmol synthesizer was successfully taken into operation increasing the operational capabilities of its midscale asset. It is expected that in 2017 Avecia’s Milford site will have nearly 3 mol oligonucleotide cGMP synthesis manufacturing capacity operational including aligned downstream assets making it the largest cGMP oligonucleotide facility in the world.
According to Avecia’s president Detlef Rethage, the 300mmol expansion in 2016 followed by the new >1.5mol facility in 2017 will help clients to receive timely oligonucleotide drug substance to advance programs in clinical trials as planned. “Avecia takes pride that the experience and innovation found within Avecia allows us to bring the new manufacturing units online in a matter of months rather than years,” said Rethage.
Analytical development laboratory and office personal now staff a new 6,500 square foot facility in Marlboro, MA. The Marlboro facility was complemented by Nitto Avecia Pharma Services, a new company created as a result of Avecia’s recent acquisition of Irvine Pharmaceutical Services (Irvine) and Avrio Biopharmaceuticals (Avrio). Nitto Avecia Pharma Services located in Irvine, CA significantly increased Avecia’s analytical capabilities and support of drug product manufacturing. Rethage said, “Nitto Avecia Pharma Services is the perfect complement to our oligonucleotide drug substance services and a key step in our strategic growth plans. Avecia Group now offers manufacturing and development services on the East Coast, West Coast and in the Midwest at our Cincinnati facility.”
As part of its planned growth, Avecia anticipates it will add many additional full-time jobs over the next three months. The new positions will specialize in microbiology, analytical chemistry, manufacturing, quality assurance and engineering. More information on open positions at any of the Avecia facilities may be found at www.aveciacareers.com.
ABOUT NITTO AVECIA, INC.
Nitto Avecia, Inc. is a recognized leader in therapeutic nucleic acid manufacturing and development services with facilities located in Milford, MA; Marlboro, MA; and Cincinnati, OH offering services for DNA, RNA and other oligonucleotides based therapeutics from milligram scale at pre-clinical stage to 1000kg + post commercial launch. More information: www.avecia.com.
Nitto Avecia is a proud member of Nitto Group. More information: www.nitto.com.
ABOUT NITTO AVECIA PHARMA SERVICES, INC.
Nitto Avecia Pharma Services is your single solution for premier contract development and manufacturing services. Nitto Avecia Pharma Services supports the pharmaceutical, biopharmaceutical, and medical device industries with a complete package of cGMP services including preformulation/formulation, parenteral manufacturing, analytical development, biopharmaceutical development, structural chemistry, analytical chemistry, microbiology, stability storage and drug delivery device testing. With three state-of-the-art facilities located on one campus in Irvine, CA, Nitto Avecia Pharma Services’ experienced staff and robust quality infrastructure delivers client-centric solutions for early phase through post-market life cycle management. Learn more at www.aveciapharma.com.
Nitto Denko Avecia, Inc.
Posted in: Press Release